Tarsus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Tarsus Pharmaceuticals Inc TARS.OQ reported a quarterly adjusted loss of 48 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -88 cents. The mean expectation of seven analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -52 cents to -24 cents per share.

• Revenue rose 151.5% to $102.66 million from a year ago; analysts expected $95.68 million.

• Tarsus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 48 cents​.

• The company reported a quarterly loss of $20.34 million.

• Tarsus Pharmaceuticals Inc shares had risen by 1.6% this quarter and lost 25.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.7% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $72.00, about 42.8% above its last closing price of $41.15

This summary was machine generated from LSEG data August 6 at 09:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)